The role of HLA-G for protection of human renal cell-carcinoma cells from immune-mediated lysis: implications for immunotherapies.

[1]  B. Seliger,et al.  Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. , 2003, Cancer research.

[2]  B. Seliger,et al.  HLA-G and MIC expression in tumors and their role in anti-tumor immunity. , 2003, Trends in immunology.

[3]  M. Weller,et al.  A Functional Role of HLA-G Expression in Human Gliomas: An Alternative Strategy of Immune Escape1 , 2002, The Journal of Immunology.

[4]  S. Ugurel,et al.  HLA-G in Melanoma: A New Strategy to Escape from Immunosurveillance? , 2002, Oncology Research and Treatment.

[5]  T. Ratliff,et al.  Immunotherapy of urologic tumors: principles and progress. , 2002, Urologic oncology.

[6]  R. Dummer,et al.  HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. , 2002, Blood.

[7]  R. Dummer,et al.  Decreased intraindividual HLA class I expression is due to reduced transcription in advanced melanoma and does not correlate with HLA-G expression. , 2001, The Journal of investigative dermatology.

[8]  S. Chouaib,et al.  Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. , 2001, Cancer research.

[9]  M. Kurrer,et al.  Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. , 2001, The American journal of pathology.

[10]  P. Selby,et al.  Renal carcinoma cell lines inhibit natural killer activity via the CD94 receptor molecule , 2001, Cancer Immunology, Immunotherapy.

[11]  J. Dausset,et al.  A soluble HLA-G protein that inhibits natural killer cell-mediated cytotoxicity. , 2001, Transplantation proceedings.

[12]  J. Dausset,et al.  HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition. , 2001, International immunology.

[13]  A. Moretta,et al.  Triggering receptors involved in natural killer cell-mediated cytotoxicity against choriocarcinoma cell lines. , 2000, Human immunology.

[14]  N. Rouas-Freiss,et al.  HLA-G and HLA-E: fundamental and Pathophysiological aspects. , 2000, Immunology today.

[15]  G. Ferrara,et al.  HLA-G, -E, -F preworkshop: tools and protocols for analysis of non-classical class I genes transcription and protein expression. , 2000, Human immunology.

[16]  B. Seliger,et al.  Antigen-processing machinery breakdown and tumor growth. , 2000, Immunology today.

[17]  S. Wagner,et al.  Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma , 2000, The Lancet.

[18]  A. Toubert,et al.  Cutting Edge: Soluble HLA-G1 Triggers CD95/CD95 Ligand-Mediated Apoptosis in Activated CD8+ Cells by Interacting with CD81 , 2000, The Journal of Immunology.

[19]  N. Won,et al.  Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas: correlation with the prognostic factors. , 2000, Archives of pathology & laboratory medicine.

[20]  M. Probst-Kepper,et al.  A New Antigen Recognized by Cytolytic T Lymphocytes on a Human Kidney Tumor Results from Reverse Strand Transcription , 1999, The Journal of experimental medicine.

[21]  Seliger,et al.  Gene Transfer of the Co‐Stimulatory Molecules B7‐1 and B7‐2 Enhances the Immunogenicity of Human Renal Cell Carcinoma to a Different Extent , 1999, Scandinavian journal of immunology.

[22]  J. Dausset,et al.  HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. , 1999, International immunology.

[23]  F. Garrido,et al.  Expression of HLA G in human tumors is not a frequent event , 1999, International journal of cancer.

[24]  N. Bander,et al.  Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  J. Dausset,et al.  Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies. , 1999, Cancer research.

[26]  B. Drénou,et al.  HLA-G protein expression is not induced during malignant transformation. , 1999, Tissue antigens.

[27]  B. Seliger,et al.  Induction of immunogenicity of a human renal‐cell carcinoma cell line by TAP1‐gene transfer , 1999, International journal of cancer.

[28]  R. Figlin.  Renal cell carcinoma: management of advanced disease. , 1999, The Journal of urology.

[29]  G. Köhler,et al.  Pro-Inflammatory and T Cell Inhibitory Cytokines Are Secreted at High Levels in Tumor Cell Cultures of Human Renal Cell Carcinoma , 1999, European Urology.

[30]  G. T. Budd,et al.  Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  D. Schendel,et al.  Human renal cell carcinoma antigen-specific CTLs: antigen-driven selection and long-term persistence in vivo. , 1998, Cancer research.

[32]  B. Seliger,et al.  IFN-gamma-mediated coordinated transcriptional regulation of the human TAP-1 and LMP-2 genes in human renal cell carcinoma. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  R. Tampé,et al.  Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. , 1996, Cancer research.

[34]  E. Halapi,et al.  Lack of interleukin‐2 (IL‐2) expression and selective expression of IL‐10 mRNA in human renal cell carcinoma , 1995, International journal of cancer.

[35]  D. Petrylak,et al.  Chemotherapy for advanced renal-cell carcinoma: 1983-1993. , 1995, Seminars in oncology.

[36]  B. Seliger,et al.  Cellular immune response to human renal‐cell carcinomas: Definition of a common antigen recognized by HLA‐A2‐restricted cytotoxic T‐Lymphocyte (CTL) clones , 1994, International journal of cancer.

[37]  E. Klein,et al.  Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation. , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[38]  D. Longo,et al.  Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. , 1993, Cancer research.

[39]  C. Cordon-Cardo,et al.  Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas. , 1991, Cancer research.

[40]  S. Kagawa,et al.  Prognostic significance of immuno-proteosome subunit expression in patients with renal-cell carcinoma: a preliminary study. , 2001, Molecular urology.

[41]  F. Marincola,et al.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.

[42]  Taylor Murray,et al.  Cancer statistics, 1998 , 1998, CA: a cancer journal for clinicians.